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Available online 7 April 2018Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a frequent and severe chronic disease drasti-
cally impairing life quality. The underlying pathomechanism is incompletely understood yet but there is convinc-
ing evidence that in at least a subset of patients ME/CFS has an autoimmune etiology. In this review, we will
discuss current autoimmune aspects forME/CFS. Immunedysregulation inME/CFS has been frequently described
including changes in cytokine profiles and immunoglobulin levels, T- and B-cell phenotype and a decrease of nat-
ural killer cell cytotoxicity. Moreover, autoantibodies against various antigens including neurotransmitter recep-
tors have been recently identified in ME/CFS individuals by several groups. Consistently, clinical trials from
Norway have shown that B-cell depletion with rituximab results in clinical benefits in about half of ME/CFS pa-
tients. Furthermore, recent studies have provided evidence for severemetabolic disturbances presumably medi-
ated by serum autoantibodies in ME/CFS. Therefore, further efforts are required to delineate the role of
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With an estimated prevalence of 0.2–0.3%, Myalgic Encephalomyeli-
tis/Chronic Fatigue Syndrome (ME/CFS) is a multisystem disease with
unknown etiology. Patients suffer from persistent exhaustion, cognitive
impairment, autonomic dysfunction, chronic pain and flu-like symp-
toms, leading to a substantial reduction of life quality [1].
ME/CFS disease onset is often reported to be triggered by infections
and the link between infections and autoimmune diseases is well
established [2]. Although the exact pathogenesis is still unknown, the
most plausible hypothesis is that dysregulation of immune system, au-
tonomic nervous system and metabolic disturbances contribute to this
complex syndrome, in which severe fatigue and cognitive impairment
are a central feature (Fig. 1). Stressful life events are frequently associ-
ated with disease onset concomitantly with a history of frequent recur-
rent infections, immune deficiency and autoimmunity [1,3]. There are
numerous studies showing immunological, genetic andmetabolic alter-
ations consistent with an autoimmune mechanism. Further, the identi-
fication of autoantibodies in ME/CFS patients and the clinical benefit
associated with B cell depleting therapy provide strong evidence that,Fig. 1. Potential pathomechanism of ME/CFS. Dysregulation of immune system, autonomic ne
which severe fatigue and cognitive impairment are core features. In most patients, disease on
risk factors. Abbreviations: Acetyl-CoA: acetyl coenzyme A, ANS: autonomic nervous system
phosphorylation, TCA: tricarboxylic acid.at least in a subset of ME/CFS patients, the disease has an autoimmune
etiology.
2. Evidence for autoimmunity in ME/CFS
2.1. Role of infection
Infection by various pathogens, including the Epstein-Barr virus
(EBV), the human herpes virus (HHV)-6 and the human parvovirus
B19, but also intracellular bacteria, are known as triggers of disease
[1,4–6]. In a subset of patients, ME/CFS begins with infectious mononu-
cleosis and evidence for a potential role of EBV in ME/CFS comes from
many studies [4,7–9]. In 1984, DuBois et al. first described patients
with mononucleosis syndrome suffering from long-lasting fatigue and
serological evidence of EBV reactivation [4] followed by a number of
studies describingME/CFS patients with serological evidence of chronic
active EBV infection [7–9]. Infectious mononucleosis is known as a risk
factor for various autoimmune diseases [2,10]. Several studies show ho-
mologies of EBV sequences with human autoantigens such as myelin
basic protein for multiple sclerosis (MS) [11]. In a study from ourrvous system (ANS) and metabolic disturbances contribute to this complex syndrome, in
set is triggered by infection with stress, immune deficiency and autoimmunity as known
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Abbreviations: ANA: antinuclear antibodies; 5-HT: 5-hydroxytryptamine; IIF: indirect im-
munofluorescence; dUTPase: deoxyuridine 5′-triphosphate nucleotidohydrolase; FM:
fibromyalgia.
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found in ME/CFS patients [9]. Homologous sequences of various
human proteins with an EBNA-6 repeat sequence might be potential
targets for antigenic mimicry.
Detection of anti-HHV-6 IgM antibodies and HHV-6 antigen in pe-
ripheral blood mononuclear cells (PBMC) and mucosa as evidence for
HHV-6 reactivation ismore frequent in patients withME/CFS compared
to healthy donors, showing that reactivation of persistent HHV-6 infec-
tion could be a trigger factor for ME/CFS [12–15]. In studies from our
group evidence for an active HHV-6, HHV-7 or B19 infection was
found in a subset of patients and was associated with subfebrility and
lymphadenopathy [16]. Others, however, showed no difference be-
tween severity of symptoms and viral load of HHV-6 and HHV-7 in
DNA from saliva and PBMCs among ME/CFS patients and controls [17].
It should be noted that HHV-6 and HHV-7 infect immune cells, prefer-
entially CD4+T cells, but also CD8+,monocytes/macrophages and nat-
ural killer (NK) cells involved in cellular, humoral and innate immune
response [18,19]. Infection of immune cells by these viruses lead to
changes in cell surface receptor expression, pro-inflammatory and
anti-inflammatory cytokine and chemokine expression level modulat-
ing local inflammation and immune response. A role for HHV-6 has
been proposed in several autoimmune diseases, including MS, autoim-
mune connective tissue diseases, and Hashimoto's thyroiditis [20]. Mo-
lecular mimicry between myelin basic protein and an HHV-6 cell
membrane protein is suggested to explain this link in MS [21]. Further,
for ME/CFS and Gulf War Illness antibodies against the human dUTPase
were reported by Halpin et al. [22]. These autoantibodies mainly occur
together with antibodies against at least one of multiple HHV-encoded
dUTPases suggesting an antigenic mimicry.
Parvovirus B19 infection has been shown to lead to development of
ME/CFS. B19-triggered ME/CFS may be associated with a persistent vire-
mia or may occur without viremia [23] and increased circulating TNF-α
and IFN-γ were shown [24]. B19-associated ME/CFS was, in some cases,
effectively treated with intravenous IgG [5,25,26]. Documented mecha-
nisms in the pathogenesis of B19-associated autoimmunity include
cross reaction of anti-B19 antibodies with human proteins, B19-induced
apoptosiswhich results in presentation of self- antigens to T lymphocytes,
and the phospholipase activity to the B19 unique VP1 protein region [23].
2.2. Immune cell alterations
Enhanced levels of immunoglobulins and alterations in B cells are
frequently found in autoimmune diseases including rheumatoid arthri-
tis (RA), systemic lupus erythematosus (SLE) and primary Sjögren's
syndrome (pSS) [27–30]. Further frequencies of CD21lowB cells are fre-
quently increased in these autoimmune diseases [27]. Consistently, al-
terations of B cell subsets are reported in ME/CFS. Elevated numbers of
CD21+ as well as CD19+ and activated CD5+ B cells were described
in ME/CFS patients [31,32]. Bradley et al. showed enhanced frequencies
of naïve and transitional B cells and diminished plasma blasts [33]. Dif-
ferently, Brenu et al. did not observe an altered frequency of plasma
blasts, but an increase of memory B cells [34]. However, nomajor alter-
ation of major B cell subpopulations was observed in other studies
[3,35]. Mensah et al. reported an increase in CD24+ B cells, a fraction
found to be elevated in autoimmune diseases [35]. Further elevated
IgG levels in a subset of ME/CFS patients were shown in several studies
[3,35,36]. Recently, a whole blood gene expression study discovered a
downregulation of genes being involved in B cell differentiation and
survival in ME/CFS [37].
T cell activation by infections could play an important role in the
onset of autoimmune diseases [38]. In ME/CFS individuals, an increased
frequency of activated T cells expressing the activation marker CD26
and HLA-DR has been shown, concomitant to lower levels of CD45RA
+CD4+ T cells [31]. Similarly, ME/CFS was associated with higher fre-
quencies of CD38 and HLA-DR co-expressing CD8+ T cells [39]. How-
ever, other authors found similar or lower expression of these markersin ME/CFS patients compared to healthy individuals [40,41]. Similarly,
there is also evidence for a decreased cytotoxicity of CD 8+ T cells in a
subset ofME/CFS patients [42–45]. Of particular interest in autoimmune
diseases are T follicular helper cells (Tfh) that induce humoral responses
at the germinal centers [46], the anti- inflammatory regulatory T cells
(Treg) and the inflammatory T helper 17 (Th17) cells that modulate
the activity of autoimmune responses [47]. The frequency of Treg has
been addressed by several authors, most of them reporting a paradoxi-
cal higher frequency of this cell population in ME/CFS [40,42,48]. How-
ever, no studies on the potential role of Tfh and Th17 cells are available
in ME/CFS yet.
In contrast to inconsistent B and T cell alterations reported in ME/
CFS, diminished numbers of circulating NK cells and reduction of their
cytotoxic activity were uniformly shown [31,40,49]. However, en-
hanced secretion of IFNγ and TNFα by the immunoregulatory CD56
bright NK cell subset was described in ME/CFS [49,50].
In summary, immune dysfunction in ME/CFS, as for other autoim-
mune disease, is a multifaceted hallmark that requires further studies
using new technologies, standardized assays and well defined cohorts
to clearly define common patterns.
2.3. Autoantibodies in ME/CFS
Several studies described autoantibodies in ME/CFS mostly against
nuclear and membrane structures and neurotransmitter receptors
(Table 1).
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Antinuclear antibodies (ANA) were found in one study in 68 % of
ME/CFS patients with the majority directed against the nuclear enve-
lope [51]. Further studies showed ANA in 68%, 57%, 23% and 13% of
ME/CFS patients [52–55]. Ortega-Hernandez et al. found dsDNA anti-
bodies in 12% of patients [56], but another study failed to show such an-
tibodies in ME/CFS (0.7%) [57].
Klein and Berg described anti-ganglioside antibodies in ME/CFS pa-
tients, but not in healthy controls [58]. In addition, they and others
found phospholipid autoantibodies in ME/CFS patients [56,58,59] and
antibodies against cardiolipin were described in 92–95% of ME/CFS pa-
tients in two studies [59,60] but only in 4% in another study [56]. Further
autoantibodies against endothelial and neuronal cells were described in
30% and 16% of patients, respectively [56].
2.3.2. Antibodies against neurotransmitter receptors and neurotransmitter
Antibodies against themuscarinicM1 acetylcholine receptor (AChR)
were reported in ME/CFS patients and were associated with muscle
weakness [54]. Evidence for a functional role of these antibodies
comes from a PET study showing reduced binding of a M AChR ligand
in brain in antibody positive ME/CFS patients [61]. Antibodies against
ß1 and ß2 adrenergic receptors (AdR) and M2/3 AChR were described
in postural tachycardia syndrome, characterized by an increased heart
rate in the absence of significant hypotension, as well as in orthostatic
hypotension. This finding is of relevance for ME/CFS as 11–40% of ME/
CFS patients concurrently suffer from postural orthostatic tachycardia
syndrome (POTS) [62–65]. In a study from our group, elevated autoan-
tibodies against both ß2-AdR and M3/4 AChR were found in a subset of
ME/CFS patients compared to healthy controls [53]. A high correlation
was found between levels of ß2 AdR autoantibodies and elevated
IgG1–3 subclasses, activated HLA-DR+ T cells and thyroid peroxidase
autoantibodies and ANA. The association of ß2 AdR autoantibodies
with immunemarkers suggests an activation of B and T cells expressing
ß2 AdRs. Further, disturbance of the AdR andM AChR function may ex-
plain symptoms of autonomic dysregulation in ME/CFS.
No differences betweenME/CFS patients and controls were found in
levels of autoantibodies directed against receptors for angiotensin,
endothelin,mu-opioid, serotonin and dopamine [53,54]. However, au-
toantibodies against serotonin have been associated with ME/CFS
[56,58].
2.3.3. Other autoantibodies
The IgM response against autoantigens formed by oxidative or
nitrosative damage was studied by Maes et al. [66]. Autoantibodies di-
rected against these neo-antigens, comprising oleic, palmitic and
myristic acid, S-farnesyl-L-cysteine, by-products of lipid peroxidation,
e.g. malondialdehyde, and N-oxide modified amino acids, e.g. nitro-ty-
rosine and nitro-tryptophan, were significantly higher in ME/CFS pa-
tients than in controls. In addition, they observed that the level of
these autoantibodies correlates with severity of illness and symptoms.
Although increased IgM antibodies against these oxidatively damaged
antigens were shown in major depression, too, a higher immune re-
sponse was found in ME/CFS [67].
2.4. Soluble markers of autoimmunity
Autoimmunity is associated with enhanced levels of circulating in-
flammatory cytokines playing an important role in the pathogenesis of
autoimmune diseases [68]. Elevated levels of cytokines related to Th1-
as well as Th2-driven responses were reported for ME/CFS in several
studies [42,69–74]. Further cytokine levels in ME/CFS were associated
with severity and duration of illness [72–74]. However, alterations in
cytokine profiles in ME/CFS were not found in all studies [75,76].
Elevated levels of B lymphocyte activating factor (BAFF) were de-
scribed in a variety of autoimmune diseases including RA, SLE and pSS
[77]. BAFF regulates the survival andmaturation of B cells andmediatesthe IL-10 production of regulatory B cells [78,79]. Elevated levels of BAFF
were shown in a subset of patients with ME/CFS in comparison to
healthy controls [80]. As the gene expression of the BAFF receptor
(TNFRSF13C) is reduced in ME/CFS, increased serum BAFF levels may
represent a compensatory mechanism [37]. Interestingly, elevated
serum BAFF levels correlated with the autoantibody production in RA,
SLE and pSS [81]. In ME/CFS an association between BAFF and autoanti-
bodies was not described so far.
Activin A and B, members of the Transforming Growth Factor β fam-
ily, are involved in the control of inflammation andmusclemass [82]. El-
evated levels of activin B as well as an elevated ratio of activin A or B to
the binding protein follostatin inME/CFS patientswere demonstrated in
a recent study [83]. An association of increased activin Awith inflamma-
tory bowel disease, RA, and asthma was already shown [82].
CD26 is a peptide-cleaving enzyme associated with immune regula-
tion. In various autoimmune diseases, such as MS, Grave's disease, and
RA increased numbers of CD26 T cells were found in inflamed tissues
and peripheral blood [84]. Fletcher et al. reported a higher frequency
of CD26 expressing CD2+ lymphocytes in ME/CFS, but a decreased ex-
pression level on T and NK cells [85]. Further, they observed a reduction
of the soluble CD26. Reduced serum CD26 levels were also reported for
SLE and RA showing an inverse correlation with disease activity [84].
Low CD26 expression on PBMCs in ME/CFS was shown to correlate
with reduced post-exercise muscle action potential, increased exercise-
mediated lipid peroxidation, reduced quality of life and enhanced pain
[86].
Other serum factors, frequently elevated in autoimmune disease like
sCD30, sCD23, soluble cytotoxic T lymphocyte-associated antigen-4
(sCTLA-4) or the soluble IL-2 receptor (sIl-2R) are not described in
ME/CFS so far [87–92].
2.5. Genetic variants associated with autoimmunity
It is well established that certain HLA alleles are associated with au-
toimmune diseases. Smith et al. showed an increased prevalence of the
class II major histocompatibility complex HLA-DQB1 ∗ 01 allele in ME/
CFS patients [93]. Two others variants of HLA-DQB1 in combination
with two RAGE-374A variants were associated with ME/CFS [94]. In an-
other study the interaction of killer cell immunoglobulin-like receptors
(KIRs) and their HLA class I epitopeswere studied. An excess of KIR3DL1
and KIR3DS1 missing their HLA-Bw4Ile80 binding motif was shown in
ME/CFS, leading potentially to an ongoing activation [95].
In the last years, genome-wide association studies revealed variants
of various genes with either gain- or loss-of-function that are associated
with the risk to develop autoimmune diseases. These single nucleotide
polymorphisms (SNP) in receptors, enzymes or transcription factors
play a role in B cell activation, T cell development, activation and prolif-
eration, and cytokine signaling which are crucial in autoimmune dis-
eases [96–100]. Further, it is becoming increasingly clear that
elements of the non-coding genome regulate a variety of normal im-
mune functions and that dysregulation of enhancer elements or long
non- coding RNA may play a key role in autoimmunity [101]. So far
only polymorphisms in cytokine as well as toll-like receptor signaling
pathways and complement cascade were studied showing an associa-
tion with ME/CFS [102,103]. Due to its regulation of the inflammatory
response the glucocorticoid receptor gene NR3C1 has gained interest.
Several variants (SNPs) within NR3C1 gene were shown to be signifi-
cantly associated with ME/CFS [104,105].
2.6. Energy metabolism and autoimmunity
Immunometabolism represents the interface between immunology
andmetabolism and is an exciting emerging field of research in autoim-
munity [106–108]. Themetabolic requirements of immune cells depend
on their state of resting or activation and differentiation. Their activation
results in a metabolic switch to aerobic glycolysis in order to provide
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supporting rapid cell proliferation and immune functions. A growing
body of evidence suggests that energy metabolism is crucial for the
maintenance of chronic inflammation, not only in terms of energy sup-
ply but also in the control of the immune response through metabolic
signals [106,107]. It has been suggested that disturbances in this intri-
cate metabolic-immune cross-talk may be closely linked with and con-
tribute to autoimmunity, although the precise pathomechanisms
involved still remain to be elucidated [107,108]. It is also striking that
several glycolytic enzymes act as autoantigens in rheumatic inflamma-
tory disorders [109], although their role in ME/CFS remains unclear.
The profound and debilitating fatigue experienced by ME/CFS indi-
viduals led to the hypothesis that energy metabolism may be dysregu-
lated. Defects in mitochondrial function in ME/CFS were shown in
various studies from our group and others [110–113]. Metabolic profile
had revealed disturbances related to energy, amino acids, nucleotides,
nitrogen metabolism and oxidative stress in ME/CFS [114–119]. A met-
abolic shift toward aerobic glycolysis resulting in insufficient tricarbox-
ylic acid (TCA) cycle and inadequate ATP production was reported
recently, although the underlying basis has yet to be established
[116,119]. Interestingly, the 2016 Fluge et al. studypoints to a secondary
metabolic change driven by a serum factor in ME/CFS patients [116].
As dysfunctional metabolic pathways can directly influence and ex-
acerbate defective immune responses, establishing the bioenergetic
metabolism status of the different subsets of immune cells in ME/CFS
has become a topic of increasing interest.
2.7. Comorbidity with autoimmune diseases
Comorbidity ofME/CFSwith various autoimmune or immune-medi-
ated diseases including fibromyalgia (FM), Hashimoto's thyroiditis andFig. 2. Autoimmune-associated comorbid conditions inME/CFS. Overall prevalence of diseases a
Encephalomyelitis/Chronic Fatigue Syndrome, POTS: postural orthostatic tachycardia syndromPOTS is observed (Fig. 2). Especially for FM there is considerable overlap
with up to 77% of patients fulfilling disease criteria for both ME/CFS and
FM [120]. FM is characterized by chronic widespread pain and is com-
mon in autoimmune diseaseswith around 50% of prevalence in patients
with RA and SLE [121,122]. According to themodified ACR 2010 criteria
FM has an overall estimated prevalence of 5.4%. In a recent study from
our group analyzing clinical subgroups in a large SpanishME/CFS cohort
was reported FM comorbidity ranging from26% to 91% [123]. In another
study including patient cohorts from Norway, UK and USA, a comorbid-
ity for ME/CFS and FM of 30% was observed [124]. In a similar manner
Hashimoto's thyroiditis characterized by elevated antibodies against
thyroid peroxidase is frequent in autoimmune disease, whereas the
overall prevalence is around 0.8% in the general population [125].
Hashimoto's thyroiditis is found in 17–20% in ME/CFS patients
[53,123]. Moreover, 11–40% of ME/CFS patients suffer from POTS [62–
65]. Interestingly, for both disorders elevated frequencies of autoanti-
bodies directed against AdRs and M AChRs were shown [53,126–128].
Furthermore, a substantial number of ME/CFS patients have a family
history of autoimmune diseases [129,130].
3. Therapies targeting autoimmunity in ME/CFS
First clear evidence for a pathogenic role of autoantibodies in ME/
CFS comes from two clinical trials with the monoclonal anti-CD20 anti-
body rituximab [129,131]. Upon depletion of CD20+ B cells with ritux-
imab, a monoclonal antibody directed against the B cell surface protein
CD20, approximately 60% of patients experienced a partial or complete,
and in some patients sustained clinical remission (Table 2). The delayed
onset of response with amedian of approximately 4months in both tri-
als suggests that clinical effects are not directlymediated bydepletion of
CD20+ B cells, but by diminishing short-lived antibody-producingnd prevalence for comorbiditywithME/CFS are indicated. Abbreviations:ME/CFS:Myalgic
e.
Table 2
Clinical trials targeting autoimmunity in ME/CFS.




RCT 28 FI & SR No difference [133]
2 g/kg/m2
3×
RCT 49 FI & SR Follow-up m3: 43% vs. 12% [134]
0.5 g/1 g/2 g/kg/m2
3×
RCT 99 FI & SR No difference [135]
1 g/kg/m2
3×




RCT 30 FI & SR Improvement 67% vs. 13% [131]
500 mg/m2 6× Single arm 29 FI & SR Improvement 62% [129]
Ongoing Trials
Cyclophosphamide (Endoxan®) Fluge et al., unpub.
Immunoadsorption [137]
Abbreviations: RCT = Randomized controlled trial; FI=Functional Improvement; SR = Symptom reduction, assessed by questionnaires; unpub.: unpublished data.
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quent wash-out of autoantibodies. Results from a multicenter con-
trolled trial with rituximab are awaited in spring 2018.
Few other treatment modalities targeting autoimmunity were eval-
uated in clinical trials in ME/CFS (Table 2). High dose intravenous IgG
therapy is efficacious in autoantibody-mediated diseases. Several intra-
venous IgG studies were performed inME/CFS during the 80's with two
randomized controlled trials with positive and twowith a negative out-
come [132]. Preliminary data from an ongoing trial in Norway with cy-
clophosphamide suggests therapeutic efficacy of this broadly
immunosuppressive drug (Fluge et al., unpublished data).
Immunoadsorption is an apheresis in which IgG is specifically removed
from plasma resulting in clinical improvement in various types of auto-
immune disease. We performed a pilot trial in 10 patients with ME/CFS
and observed first evidence for efficacy [137].4. Conclusion
There is compelling evidence that autoimmune mechanisms play a
role in ME/CFS. However clinical heterogeneity in disease onset (infec-
tion versus non-infection triggered), presence of immune-associated
symptoms, and divergent immunological alterations point to the exis-
tence of subgroups of ME/CFS patients with possibly different
pathomechanisms. Therefore, it is important to identify clinically useful
diagnostic markers to select patients with autoimmune-mediated dis-
ease for clinical trials. The search for autoantibodies is of great impor-
tance enabling to develop potential biomarkers for diagnosis and
providing a rationale for therapeutic interventions. Encouraging results
from first clinical trials warrant larger studies with rituximab and other
strategies targeting autoantibodies.Funding
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